Dr. Margaret T. Kasner

Hematology Oncology | Oncology | Palliative Medicine

Jefferson Health

1101 Chestnut Street, Floor 14,

Philadelphia, PA

Accepting New Patients

Offers Telehealth

22 Years of Experience

Jefferson Health

1101 Chestnut Street, Floor 14,

Philadelphia, PA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margaret Kasner is an Oncologist and a Palliative Medicine provider in Philadelphia, Pennsylvania. Dr. Kasner has been practicing medicine for over 22 years and is rated as an Experienced provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is currently accepting new patients.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Perelman School Of Medicine At The University Of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Specialties

Hematology Oncology

Oncology

Palliative Medicine

Licenses

Internal Medicine in PA

Board Certifications

Medical Oncology

Hematology

Fellowships

Hospital of the University of Pennsylvania

Hospital Affiliations

Thomas Jefferson University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107

Call: 215-955-8874

Additional Areas of Focus

Dr. Kasner has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Aplastic Anemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Enrollment Status: Completed

Publish Date: December 15, 2025

Intervention Type: Drug, Radiation, Genetic

Study Phase: Phase 2

A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy

Enrollment Status: Completed

Publish Date: December 10, 2025

Intervention Type: Drug

Study Drugs: Sirolimus, Azacitidine

Study Phase: Phase 2

A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies

Enrollment Status: Completed

Publish Date: October 30, 2025

Intervention Type: Drug, Radiation, Procedure, Other, Biological

Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes

Study Phase: Phase 2

A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Completed

Publish Date: May 15, 2025

Intervention Type: Drug

Study Drugs: Palbociclib, Dexamethasone

Study Phase: Phase 1

A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma

Enrollment Status: Withdrawn

Publish Date: May 02, 2025

Intervention Type: Drug, Radiation, Biological, Procedure

Study Phase: Phase 1

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas

Enrollment Status: Completed

Publish Date: April 30, 2025

Intervention Type: Drug, Procedure, Genetic

Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide

Study Phase: Phase 1/Phase 2

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Enrollment Status: Completed

Publish Date: April 30, 2025

Intervention Type: Drug, Biological, Procedure, Radiation

Study Phase: Phase 2

A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies

Enrollment Status: Completed

Publish Date: April 30, 2025

Intervention Type: Device

Study Phase: Phase 2

A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia

Enrollment Status: Completed

Publish Date: April 29, 2025

Intervention Type: Drug

Study Phase: Early Phase 1

A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies

Enrollment Status: Completed

Publish Date: April 24, 2025

Intervention Type: Drug, Radiation, Other, Biological, Procedure

Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil

Study Phase: Phase 2

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Enrollment Status: Completed

Publish Date: October 26, 2024

Intervention Type: Drug

Study Drug: Tislelizumab

Study Phase: Phase 2

A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes

Enrollment Status: Terminated

Publish Date: July 15, 2024

Intervention Type: Drug

Study Drugs: ONO-7475, Venetoclax

Study Phase: Phase 1/Phase 2

A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia

Enrollment Status: Completed

Publish Date: October 10, 2023

Intervention Type: Drug

Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine

Study Phase: Phase 2

A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies

Enrollment Status: Completed

Publish Date: November 17, 2022

Intervention Type: Radiation, Drug, Biological, Device, Procedure

Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion

Study Phase: Phase 2

View 13 Less Clinical Trials

42 Total Publications

Anexelekto (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study.

Journal: Acta haematologica

Published: April 10, 2025

View All 42 Publications

Similar Doctors

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Jakub Svoboda

Oncology | Hematology Oncology | Hematology

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Jakub Svoboda

Oncology | Hematology Oncology | Hematology

University Of Penn - Medical Group

3400 Civic Ctr Blvd,

Philadelphia, PA

(1.9 miles away)

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Jakub Svoboda is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Svoboda is rated as an Elite provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Sandra F. Schnall

Hematology Oncology | Hematology | Oncology

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Sandra F. Schnall

Hematology Oncology | Hematology | Oncology

825 Old Lancaster Rd, Suite 320,

Bryn Mawr, PA

(10.0 miles away)

610-527-3800

Languages Spoken:

English

See accepted insurances

Sandra Schnall is a Hematologist Oncology specialist and a Hematologist in Bryn Mawr, Pennsylvania. Dr. Schnall is rated as a Distinguished provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). Her top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, and Bone Marrow Aspiration.

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Lindsay R. Wilde

Oncology | Hematology

Experienced in Acute Erythroid Leukemia (AEL)

Dr. Lindsay R. Wilde

Oncology | Hematology

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14,

Philadelphia, PA

(0.2 miles away)

215-955-8874

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Lindsay Wilde is an Oncologist and a Hematologist in Philadelphia, Pennsylvania. Dr. Wilde is rated as a Distinguished provider by MediFind in the treatment of Acute Erythroid Leukemia (AEL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Febrile Neutropenia, Chronic Familial Neutropenia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Wilde is currently accepting new patients.

VIEW MORE ACUTE ERYTHROID LEUKEMIA (AEL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kasner's expertise for a condition

ConditionClose